当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
BEXSERO, Meningococcal Group B Vaccine
申请企业
GlaxoSmithKline Biologicals
药品名称
BEXSERO, Meningococcal Group B Vaccine
承诺描述
To conduct a safety and immunogenicity study (V72_79) to assess concomitant use of BEXSERO with a second dose of Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine in persons 16 years through 18 years of age.
承诺状态描述
The final protocol due date has passed with no final protocol received.